Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
International journal of biological macromolecules
2024
|
| Subjects: | |
| Online Access: | https://pubmed.ncbi.nlm.nih.gov/39577534/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Marine polysaccharides for antibiofilm application: A focus on biomedical fields. Jeong, Geum-Jae Khan, Fazlurrahman Kim, Do-Kyun Cho, Kyung-Jin Tabassum, Nazia Choudhury, Arunabh Hassan, Md Imtaiyaz Jung, Won-Kyo Kim, Hyun-Woo Kim, Young-Mog Biofilms Polysaccharides Aquatic Organisms Humans Animals Anti-Bacterial Agents Biocompatible Materials Microbial pathogens such as bacteria and fungi form biofilms, which represent substantial hurdles in treating human illness owing to their adaptive resistance mechanism to conventional antibiotics. Biofilm may cause persistent infection in a variety of bodily areas, including wounds, oral cavity, and vaginal canal. Using invasive devices such as implants and catheters contributes significantly to developing healthcare-associated infections because they offer an ideal surface for biofilm formation. Marine organisms produce a variety of polysaccharides, which have recently attracted worldwide attention due to their biochemical features, various applications, and advantageous properties such as bioactivity, biodegradability, and biocompatibility. Because of their antimicrobial and antibiofilm features, several polysaccharides such as chitosan, fucoidan, carrageenan, alginate, and hyaluronic acid have been used to treat infected wounds as well as ophthalmic, oral, and vaginal infections. In addition, marine polysaccharides are currently employed as coatings on medical devices and implant materials, alone or in combination with other bioactive substances or nanomaterials, to protect the materials' undertones from microbial contamination. This review discussed the recent advancements in marine polysaccharides and their derivatives as a therapeutic potential against biofilm-associated diseases. The potential obstacles in the scalability of their production, clinical translation, and/or regulatory hurdles have also been discussed.